ALLMedicine™ Atrial Flutter Center
Research & Reviews 1,215 results
https://clinicaltrials.gov/ct2/show/NCT04658940
Aug 3rd, 2022 - The Acutus Medical AcQForce Flutter clinical study is a prospective, multi-center, non-randomized global study designed to demonstrate the safety and effectiveness of the AcQBlate Force Sensing Ablation System in the ablation management of symptom...
https://doi.org/10.1093/ehjqcco/qcac045
European Heart Journal. Quality of Care & Clinical Outcomes; Kobo O, Raisi-Estabragh Z et. al.
Aug 2nd, 2022 - There is limited data on temporal trends of cardiovascular hospitalizations and outcomes amongst cancer patients. We describe the distribution, trends of admissions, and in-hospital mortality associated with key cardiovascular diseases among cance...
https://doi.org/10.1002/ehf2.14082
ESC Heart Failure; Touboul O, Algalarrondo V et. al.
Jul 30th, 2022 - Atrial fibrillation (AF)/atrial flutter is common during cardiac amyloidosis (CA). Electrical cardioversion (EC) is a strategy to restore sinus rhythm (SR). However, left atrial thrombus (LAT) represents a contraindication for EC. CA patients with...
https://clinicaltrials.gov/ct2/show/NCT05213104
Jul 25th, 2022 - AFLOAT is a national, multicenter, randomized, controlled, open-label superiority study with a blind evaluation of all the endpoints (PROBE design). The interventional phase is followed by an observational phase as long as the patient is implanted...
https://doi.org/10.1111/anec.12997
Annals of Noninvasive Electrocardiology : the Official Jo... Ishimura M, Yamamoto K et. al.
Jul 22nd, 2022 - Roof-dependent atrial flutter (AFL) is a major tachyarrhythmia rotating in the left atrium (LA). Here, we describe a case of roof-dependent AFL during atrial fibrillation ablation. LA posterior wall (LAPW) debulking ablation was performed before t...
Guidelines 3 results
https://doi.org/10.1016/j.jacc.2020.08.037
Journal of the American College of Cardiology; Heidenreich PA, Estes NAM et. al.
Dec 12th, 2020 - 2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.|2020|Hei...
https://doi.org/10.1016/j.cjca.2010.11.007
The Canadian Journal of Cardiology; Cairns JA, Connolly S et. al.
Feb 19th, 2011 - The stroke rate in atrial fibrillation is 4.5% per year, with death or permanent disability in over half. The risk of stroke varies from under 1% to over 20% per year, related to the risk factors of congestive heart failure, hypertension, age, dia...
https://doi.org/10.1161/CIRCULATIONAHA.107.187192
Circulation Estes NA, Halperin JL et. al.
Feb 20th, 2008 - ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the...
Drugs 207 results see all →
Clinicaltrials.gov 180 results
https://clinicaltrials.gov/ct2/show/NCT04658940
Aug 3rd, 2022 - The Acutus Medical AcQForce Flutter clinical study is a prospective, multi-center, non-randomized global study designed to demonstrate the safety and effectiveness of the AcQBlate Force Sensing Ablation System in the ablation management of symptom...
https://clinicaltrials.gov/ct2/show/NCT05213104
Jul 25th, 2022 - AFLOAT is a national, multicenter, randomized, controlled, open-label superiority study with a blind evaluation of all the endpoints (PROBE design). The interventional phase is followed by an observational phase as long as the patient is implanted...
https://clinicaltrials.gov/ct2/show/NCT05016791
Jul 20th, 2022 - Atrial fibrillation (AF) is a heart rhythm disorder associated with debillitating symptoms, psychological distress and heart failure. It can also significantly increase an individuals stroke risk. Catheter ablation (CA) for AF is the most effectiv...
https://clinicaltrials.gov/ct2/show/NCT03919097
Jul 19th, 2022 - Atrial flutter is a common condition that is effectively treated by ablation using radiofrequency. Due to its feasibility, effectiveness and low procedural risk, radiofrequency ablation is a first-line treatment of atrial flutter. Several studies ...
https://clinicaltrials.gov/ct2/show/NCT05456204
Jul 15th, 2022 - Atrial fibrillation and atrial flutter are the most common arrhythmias among the adult population of the world, their share in the population is from 2 to 4% and continues to grow. Modern highly effective methods of minimally invasive surgical tre...
News 200 results
https://www.medscape.com/viewarticle/978761
Aug 5th, 2022 - Although cardiovascular disease (CVD) is known to often strike the mortal blow in patients with cancer, a national analysis puts in stark relief the burden of CV-related hospitalizations in this vulnerable population. Results show that between 200...
https://www.medscape.com/viewarticle/976723
Jul 7th, 2022 - Over roughly the past decade, there has been rapid development and swift uptake of consumer technology capable of recording physiologic data relevant to cardiac health, including physical activity, heart rate, electrocardiograms, and episodes of a...
https://www.mdedge.com/jcomjournal/article/252962/cardiology/early-hospital-discharge-following-pci-patients-stemi
Thai Nguyen, MD, Albert Chan, MD et. al.
Mar 21st, 2022 - Study Overview Objective: To assess the safety and efficacy of early hospital discharge (EHD) for selected low-risk patients with ST-segment elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (PCI). Design: Si.
https://www.onclive.com/view/ibrutinib-therapy-for-cll-long-term-data
Jan 20th, 2022 - William Wierda, MD, PhD: Let’s start with the updates that we’ve had available over the last year. Jackie, we can start with you and if you could sort of give us your thoughts and comments around recent updates over the last data about ibrutinib [...
https://www.onclive.com/view/ibrutinib-plus-rituximab-and-venetoclax-followed-by-risk-stratified-chemoimmunotherapy
Jan 3rd, 2022 - Preetesh Jain, MD, PhD, discusses data from the following study: Ibrutinib plus rituximab and venetoclax followed by risk-stratified observation or short-course R-hyper-CVAD [rituximab, cyclophosphamide, vincristine, doxorubicin hydrochloride, de...